← Back to Search

Hemoglobin-based Oxygen Carrier

PP-007 for Stroke (HEMERA-1 Trial)

Phase 1
Waitlist Available
Research Sponsored by Prolong Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights

HEMERA-1 Trial Summary

This trial will study the safety of giving patients with Acute Ischemic Stroke a single IV infusion of PP-007, a pegylated form of bovine carboxyhemoglobin. The study will also look at the effects of PP-007 on collateral flow, infarct size, and functional outcome. Patients will be randomized to either standard of care (excluding tPA) or to receive PP-007. Patients may also receive thrombectomy.

Eligible Conditions
  • Stroke

HEMERA-1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
12-lead ECG
AESI, Blood pressure
AESI, Liver panel
+13 more
Secondary outcome measures
Clinical Activity
Clinical Activity, ASITN collateral score
Clinical Activity, NIHSS and mRS
+3 more

HEMERA-1 Trial Design

2Treatment groups
Experimental Treatment
Group I: Standard of CareExperimental Treatment1 Intervention
Patients randomized to receive this treatment will receive standard of care appropriate for the condition.
Group II: PP-007Experimental Treatment1 Intervention
Patients randomized to receive this treatment will receive a single infusion of PP-007
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PP-007
2021
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

Prolong PharmaceuticalsLead Sponsor
14 Previous Clinical Trials
289 Total Patients Enrolled
Prayag Shah, MD, MBAStudy DirectorProlong Pharmaceuticals, LLC
Prayag N Shah, MD, MBAStudy DirectorProlong Pharmaceuticals, LLC

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety Study of PP-007 in Subjects With Acute Ischemic Stroke
2021. "Safety Study of PP-007 in Subjects With Acute Ischemic Stroke". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04677777.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top